TRACON Pharmaceuticals In... (TCON)
undefined
undefined%
At close: undefined
1.08
3254.04%
After-hours Jun 27, 2024, 07:53 PM EDT

Company Description

TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer in the United States.

Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of soft tissue sarcoma; and YH001, an investigational humanized CTLA-4 IgG1 monoclonal antibody for the treatment of various cancer indications.

The company's clinical stage products also include TRC102, a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors and lymphomas, lung cancer, and glioblastoma; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors.

It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309; Case Western Reserve University for the development of TRC102; and cooperative research and development agreement with National Cancer Institute.

The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005.

TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California.

TRACON Pharmaceuticals Inc.
TRACON Pharmaceuticals Inc. logo
Country United States
IPO Date Jan 30, 2015
Industry Biotechnology
Sector Healthcare
Employees 17
CEO Craig R. Jalbert CIRA

Contact Details

Address:
4350 La Jolla Village Drive
San Diego, California
United States
Website https://www.traconpharma.com

Stock Details

Ticker Symbol TCON
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001394319
CUSIP Number 89237H209
ISIN Number US89237H2094
Employer ID 00-0000000
SIC Code 2836

Key Executives

Name Position
Craig R. Jalbert CIRA Chief Executive Officer, President, Treasurer, Secretary & Director
Dr. James L. Freddo M.D. Chief Medical Officer
Ya Huang Executive Director of Statistical Programming

Latest SEC Filings

Date Type Title
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Nov 07, 2024 15-12G Filing
Oct 31, 2024 RW Filing
Oct 31, 2024 POS AM Filing
Oct 31, 2024 POS AM Filing
Oct 31, 2024 POS AM Filing
Oct 31, 2024 POS AM Filing
Oct 31, 2024 POS AM Filing
Oct 31, 2024 POS AM Filing
Oct 31, 2024 POS AM Filing